Tranzyme Pharma to Present TZP-102 Phase 2 Data Showing Decrease in Severity of Symptoms of Gastroparesis

Oral Presentation During the Plenary Session for Functional GI Disorders at the 2010 American College of Gastroenterology Meeting (ACG) in San Antonio, TX October 20, 2010

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine and Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present preliminary TZP-102 Phase 2 data at this year’s ACG annual meeting. The event is being held at the Henry B. Gonzalez Convention Center in San Antonio TX, October 15-20, 2010. Professor Wo is scheduled to speak on Wednesday, October 20th at 8:50am in Ballroom C1.

The presentation entitled, “An orally administered ghrelin agonist (TZP-102) decreases the overall severity of symptoms of diabetic gastroparesis (GP): Phase 2 Proof of Concept Study – Preliminary results” will summarize the beneficial effects of TZP-102 on the multi-component gastroparesis symptom complex.

Gastroparesis, a syndrome dominated by early satiety, postprandial fullness and nausea, disrupts daily quality of life and, in severe cases, may require hospitalization. Gastroparesis complicates in particular the management of patients with diabetes and overall, comprises an area of extreme unmet medical need. Currently, there are no safe and effective treatments for gastroparesis. Earlier prescription medications used to treat this condition were either withdrawn from the market or must carry a “black box” warning due to serious side effects.

About Tranzyme Pharma

Tranzyme Pharma is a clinical-stage drug development company that discovers and develops novel small molecule macrocyclic drugs for both acute care (hospital-based) and chronic indications with significant unmet medical needs. The Company's pipeline is derived from its proprietary drug discovery (chemistry) technology, MATCH™, and targets products for gastrointestinal motility, metabolic diseases and cancer supportive care.

Tranzyme has two corporate partnerships -- a broad drug discovery partnership with Bristol-Myers Squibb to discover, develop and commercialize novel drug candidates in multiple therapeutic areas, and a European licensing agreement with Norgine for the co-development of Tranzyme’s intravenous ghrelin agonist, ulimorelin. www.tranzyme.com.



CONTACT:

Tranzyme Pharma
Vipin K. Garg, PhD, 919-313-4764
President and CEO
[email protected]
Jennifer A. Filbey, PhD, 256-417-8568
VP, Business Development
[email protected]
Susan S. Josselyn, 919-313-4761
Corporate Communications Manager
[email protected]

KEYWORDS:   United States  North America  North Carolina  Texas

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Oncology  Pharmaceutical  Radiology  Diabetes

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.